Eiropas Savienība - latviešu - EMA (European Medicines Agency)

norgine b.v. - dzelzs maltols - anēmija, dzelzs deficīts - antianēmiski līdzekļi - feraccru ir norādīts ārstēšanai pieaugušajiem dzelzs deficīts.

Latvija - latviešu - Zāļu valsts aģentūra

medis gmbh, austria - rozmarīna ēteriskā eļcļca - krēms - 100 mg/g

Latvija - latviešu - Pārtikas un veterinārais dienests, Zemkopības ministrija

sabiedrības “arkopharma” grupa “nutripharma ltd” - kapsula

Latvija - latviešu - Pārtikas un veterinārais dienests, Zemkopības ministrija

sabiedrības “arkopharma” grupa “nutripharma ltd” - kapsula

Latvija - latviešu - Pārtikas un veterinārais dienests, Zemkopības ministrija

sabiedrības ″arkopharma″ grupa ″nutripharma ltd″ - kapsula

Latvija - latviešu - Zāļu valsts aģentūra

b.braun melsungen ag, germany - isoleucinum, leucinum, lysinum, methioninum, phenylalaninum, threoninum, tryptophanum, valinum, argininum, histidinum, alaninum, acidum asparticum, acidum glutamicum, glycinum, prolinum, serinum, natrii hydroxidum, natrii chloridum, natrii acetas trihydricus, kalii acetas, magnesii acetas tetrahydricus, calcii chloridum dihydricum, glucosum monohydricum, natrii dihydrogenophosphas dihydricus, zinci acetas dihydricus, triglycerida saturata media, soiae oleum, omega-3 acidorum triglycerida - emulsija infūzijām

Latvija - latviešu - Pārtikas un veterinārais dienests, Zemkopības ministrija

medisorb, as - tablete

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

astrazeneca ab - tremelimumab - carcinoma, hepatocellular - antineoplastiski līdzekļi - imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc). imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - antineoplastiski līdzekļi - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.

Latvija - latviešu - Pārtikas un veterinārais dienests, Zemkopības ministrija

medisana gmbh - kapsula